FAIR VALUE MEASUREMENTS (Details Narrative) - USD ($)		12 Months Ended
Oct. 06, 2023	Jun. 30, 2025	Jun. 30, 2024
Fair Value Disclosures [Abstract]
Available for sale securities aggregate cost		$ 3,551,000	$ 3,964,000
Investments included net unrealized gains (losses)		3,300,000	1,800,000
Gross unrealized gains		3,500,000	2,100,000
Gross unrealized losses		213,000	261,000
Marketable equity securities		$ 1,000,000.0	$ 987,000
Warrant description	On October 6, 2023, in conjunction with the execution of a supply agreement with Monogram Technologies, Inc., formerly Monogram Orthopaedics Inc. (“Monogram”), we exercised a warrant to purchase common stock of Monogram (the “Monogram Warrant”) in full in cash totaling $1,250,000 and received 1,828,551 shares of Monogram common stock (NasdaqCM: MGRM). Additionally, in June 2025 we exercised additional warrants in full in cash totaling $900,000 and received an additional 85,705 shares of common stock and 298,122 shares of Series D Preferred Stock. On July 14, 2025, the Series D preferred stock converted into the same number of common shares pursuant to the terms of the underlying certificate. The fair value of the Monogram common stock and preferred stock is reflected in marketable equity securities – short term in the tables above.

Investments included net unrealized gains (losses)

3,300,000

1,800,000

213,000

261,000

On October 6, 2023, in conjunction with the execution of a supply agreement with Monogram Technologies, Inc., formerly Monogram Orthopaedics Inc. (“Monogram”), we exercised a warrant to purchase common stock of Monogram (the “Monogram Warrant”) in full in cash totaling $1,250,000 and received 1,828,551 shares of Monogram common stock (NasdaqCM: MGRM). Additionally, in June 2025 we exercised additional warrants in full in cash totaling $900,000 and received an additional 85,705 shares of common stock and 298,122 shares of Series D Preferred Stock. On July 14, 2025, the Series D preferred stock converted into the same number of common shares pursuant to the terms of the underlying certificate. The fair value of the Monogram common stock and preferred stock is reflected in marketable equity securities – short term in the tables above.